Edward R. Reines (Ed)

Partner

硅谷 + 1.650.739.3982

联系：

Share

A first-chair trial lawyer and trusted appellate advocate, Ed Reines has extensive experience in competitor vs. competitor disputes involving the life sciences, biotech, and high-technology industries.

Ed has successfully represented clients in high-stakes disputes for decades. His recent achievements before joining Jones Day in 2025 include overturning a $96 million verdict in a patent case involving genetic technologies, winning a $45 million verdict in a Lanham Act false advertising lawsuit regarding diagnostic tests, a $24 million verdict in a case related to prenatal genetic testing methods with a defense verdict on a $105 million contract claim, scoring a judgment of more than $50 million in a case involving microfluidic technologies, and a complete summary judgment in a sprawling multidistrict patent litigation.

Ed is the recipient of numerous accolades by leading legal publications, including as a top litigator, having been named an MVP by Law360 twice; "General Patent Litigator of the Year, California," by LMG Life Sciences; and among the "Top 100 Lawyers in California" and "Top IP Lawyers in California" by the Daily Journal many times.

Ed is past president of the Federal Circuit Bar Association; past president of the Federal Bar Association's Northern District of California Chapter, where he chaired the N.D. Cal Patent Rules Committee for years and helped pioneer the patent rules used around the country. He also teaches patent litigation at UC Berkeley Law School. Ed is dedicated to supporting disabled veterans rights, and he recently joined the board of directors of Grateful Guitars, a nonprofit that donates guitars — modeled on those used by legendary jam band musicians — to up-and-coming and struggling musicians.

经验

  • FICT secures $50 million jury verdict in commercial disputeJones Day, as lead counsel, together with Weil as co-counsel, secured a $50 million jury verdict for FICT Limited by establishing that Ampere Computing LLC ("Ampere") breached the parties' seven-year agreement.
  • Parse secures Federal Circuit affirmance of PTAB patent obviousness decision involving single cell analysis claimsJones Day secured a complete appellate victory for Parse Biosciences, Inc. ("Parse") when the Federal Circuit affirmed three Patent Trial and Appeal Board (PTAB) final written decisions holding every claim of three 10x Genomics, Inc. ("10x") patents unpatentable as obvious.
  • Guardant Health defends patent infringement allegations in DDE over its cancer testing technologyJones Day is defending Guardant Health, Inc. ("Guardant") in a patent infringement case brought by Cold Spring Harbor Laboratory ("CSHL") in the District of Delaware relating to the use of DNA sequencing for cancer diagnostic testing.
    •

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice